BR112015011974A8 - derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica - Google Patents

derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica Download PDF

Info

Publication number
BR112015011974A8
BR112015011974A8 BR112015011974A BR112015011974A BR112015011974A8 BR 112015011974 A8 BR112015011974 A8 BR 112015011974A8 BR 112015011974 A BR112015011974 A BR 112015011974A BR 112015011974 A BR112015011974 A BR 112015011974A BR 112015011974 A8 BR112015011974 A8 BR 112015011974A8
Authority
BR
Brazil
Prior art keywords
carboxamide derivatives
medicament
production
pharmaceutical composition
azaquinazoline
Prior art date
Application number
BR112015011974A
Other languages
English (en)
Other versions
BR112015011974A2 (pt
Inventor
Goutopoulos Andreas
R Huck Bayard
Neagu Constantin
Potnick Justin
Celeste Deselm Lizbeth
W Jr Cronin Mark
Boivin Roch
Lan Ruoxi
L Johnson Theresa
Chen Xiaoling
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112015011974A2 publication Critical patent/BR112015011974A2/pt
Publication of BR112015011974A8 publication Critical patent/BR112015011974A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "derivados de azaquinazolina carboxamida". a presente invenção refere-se a novos derivados de azaquinazolina carboxamida de fórmula (i) (i) em que w1, w2, w3, w4, r1, r2, r3 e m que foram definidos acima, são inibidores de p70s6k, e podem ser empregados, inter alia, para o tratamento de distúrbios hiperproliferativos.
BR112015011974A 2012-11-29 2013-11-27 derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica BR112015011974A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731075P 2012-11-29 2012-11-29
PCT/US2013/072141 WO2014085528A1 (en) 2012-11-29 2013-11-27 Azaquinazoline carboxamide derivatives

Publications (2)

Publication Number Publication Date
BR112015011974A2 BR112015011974A2 (pt) 2017-07-11
BR112015011974A8 true BR112015011974A8 (pt) 2019-10-08

Family

ID=49759613

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011974A BR112015011974A8 (pt) 2012-11-29 2013-11-27 derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica

Country Status (19)

Country Link
US (3) US9440968B2 (pt)
EP (1) EP2925747B1 (pt)
JP (1) JP6290917B2 (pt)
KR (1) KR20150090044A (pt)
CN (1) CN105793254B (pt)
AU (1) AU2013352261B2 (pt)
BR (1) BR112015011974A8 (pt)
CA (1) CA2887539C (pt)
CL (1) CL2015001187A1 (pt)
EA (2) EA033655B1 (pt)
ES (1) ES2821102T3 (pt)
IL (2) IL239054B (pt)
MX (1) MX2015006516A (pt)
NZ (1) NZ706418A (pt)
PE (1) PE20151782A1 (pt)
PH (2) PH12015500712B1 (pt)
SG (2) SG10201800741QA (pt)
UA (1) UA115154C2 (pt)
WO (1) WO2014085528A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015006516A (es) * 2012-11-29 2015-08-14 Merck Patent Gmbh Derivados de azaquinolin-carboxamida.
JP6821670B2 (ja) 2015-10-02 2021-01-27 センティネル・オンコロジー・リミテッドＳｅｎｔｉｎｅｌ Ｏｎｃｏｌｏｇｙ Ｌｉｍｉｔｅｄ 薬学的化合物
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
BR112022008131A2 (pt) 2019-11-01 2022-07-19 Syngenta Crop Protection Ag Compostos heteroaromáticos bicíclicos fundidos pesticidamente ativos
KR20240024926A (ko) 2021-06-24 2024-02-26 신젠타 크롭 프로텍션 아게 살충제로서의 2-[3-[1[(퀴나졸린-4-일)아미노]에틸]피라진-2-일]티아졸-5-카르보니트릴 유도체 및 유사한 화합물
WO2023247360A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
CN117304182A (zh) * 2022-06-22 2023-12-29 上海海和药物研究开发股份有限公司 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA287539A (en) * 1929-02-26 William Hallden Karl Severing apparatus
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JP2000505109A (ja) * 1996-11-27 2000-04-25 ファイザー・インク 縮合二環式ピリミジン誘導体
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003252314A1 (en) * 2002-08-09 2004-02-25 Kyorin Pharmaceutical Co., Ltd. 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
CA2539339A1 (en) 2003-09-30 2005-04-14 Irm Llc Compounds and compositions as protein kinase inhibitors
JP4800216B2 (ja) 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
US20080262021A1 (en) 2003-11-21 2008-10-23 Novartis Ag 1H-Imidazoquinoline Derivatives as Prote In Kinase Inhibitors
ATE447957T1 (de) 2003-12-09 2009-11-15 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
ATE543821T1 (de) 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
WO2006136821A1 (en) 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
WO2007060404A1 (en) 2005-11-22 2007-05-31 Kudos Pharmaceuticals Limited PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
CN101641358A (zh) 2007-03-23 2010-02-03 霍夫曼-拉罗奇有限公司 氮杂-吡啶并嘧啶酮衍生物
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
CN101230045B (zh) * 2008-02-14 2013-04-10 沈阳药科大学 芳环并三嗪类衍生物及其应用
SG173473A1 (en) * 2009-02-11 2011-09-29 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
CN102858754A (zh) * 2009-08-28 2013-01-02 阵列生物制药公司 Raf抑制剂化合物及其使用方法
EA028012B1 (ru) * 2010-07-29 2017-09-29 Мерк Патент Гмбх Циклический амин-азагетероциклический карбоксамид
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
EA023821B1 (ru) * 2010-11-24 2016-07-29 Мерк Патент Гмбх Хиназолинкарбоксамидазетидины, их применение в лечении гиперпролиферативных заболеваний и содержащие их композиции
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
MX2015006516A (es) * 2012-11-29 2015-08-14 Merck Patent Gmbh Derivados de azaquinolin-carboxamida.

Also Published As

Publication number Publication date
PH12016502534B1 (en) 2017-11-20
BR112015011974A2 (pt) 2017-07-11
JP2016501229A (ja) 2016-01-18
EA029144B1 (ru) 2018-02-28
IL239054A0 (en) 2015-07-30
IL256646A (en) 2018-02-28
US20160340323A1 (en) 2016-11-24
CA2887539C (en) 2021-10-26
CN105793254A (zh) 2016-07-20
US20180237402A1 (en) 2018-08-23
SG10201800741QA (en) 2018-03-28
US20150259339A1 (en) 2015-09-17
US10233160B2 (en) 2019-03-19
UA115154C2 (uk) 2017-09-25
SG11201502503RA (en) 2015-04-29
MX2015006516A (es) 2015-08-14
EA201500573A1 (ru) 2016-02-29
CL2015001187A1 (es) 2015-08-28
CN105793254B (zh) 2020-10-23
WO2014085528A1 (en) 2014-06-05
CA2887539A1 (en) 2014-06-05
PH12015500712A1 (en) 2015-05-18
KR20150090044A (ko) 2015-08-05
NZ706418A (en) 2019-09-27
PH12015500712B1 (en) 2015-05-18
EP2925747A1 (en) 2015-10-07
IL239054B (en) 2021-04-29
PE20151782A1 (es) 2015-12-02
EA201792187A1 (ru) 2018-02-28
US9440968B2 (en) 2016-09-13
EP2925747B1 (en) 2020-06-24
AU2013352261B2 (en) 2018-05-10
JP6290917B2 (ja) 2018-03-07
ES2821102T3 (es) 2021-04-23
US9981925B2 (en) 2018-05-29
EA033655B1 (ru) 2019-11-13
AU2013352261A1 (en) 2015-04-23
IL256646B (en) 2020-03-31
PH12016502534A1 (en) 2017-11-20

Similar Documents

Publication Publication Date Title
BR112015011974A8 (pt) derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica
BR112014026383A2 (pt) derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl1
BR112014027584A2 (pt) compostos e composições para inibir a atividade de abl1, abl2 e bcr-abl1
BR112015001608A2 (pt) inibidor lfa-1 e polimorfo do mesmo
EA201390934A1 (ru) Композиции и способы модулирования fxr
BR112014027181A2 (pt) derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
BR112014030795A2 (pt) composto, composição farmacêutica, uso de um composto e processo para preparação de um composto
BR112014001801A2 (pt) indazóis
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
GEP20146197B (en) New compounds
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
BR112013020536A2 (pt) 1,4-oxazepinas como inibidores de bace1 e/ou bace2
PH12017500351A1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
BRPI0808353B8 (pt) usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados
EA201591180A1 (ru) Составы ингибитора lfa-1
BR112015006063A2 (pt) compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
BR112015001524A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de déficits cognitivos e uso de um composto
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2015006807A (es) Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements